BBB National Programs' NAD mandates that Good Life Meds cease unsupported advertising for its compounded Tirzepatide+ offerings following a formal challenge from Eli Lilly.
Eli Lilly is the challenger behind the NAD recommendation that Good Life Meds stop certain health and personalization claims for compounded Tirzepatide+ products. The recommendation supports Lilly's position against compounded versions, but it is a non-binding advertising-industry ruling about one seller and contains no financial figures, so the effect on Lilly's share price over the coming weeks is likely limited.
The National Advertising Division (NAD) has ruled that Good Life Meds must discontinue specific health and personalization claims regarding its compounded Tirzepatide+ products. The decision follows a challenge by Eli Lilly, which argued that the company's marketing lacked sufficient evidence to support claims about safety, efficacy, and weight loss results.
Eli Lilly challenged the advertising claims made by Good Life Meds, arguing that the company lacked the necessary evidence to support its marketing regarding the safety, efficacy, and personalization of its compounded Tirzepatide+ products.